Allex (desloratadine)
- Region
- 🇪🇺 EU
- Active substance
- desloratadine
- Company
- Schering-Plough Europe
- Status
- Withdrawn
- Therapeutic area
- Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal
- EU approval
- Mon 15 Jan 2001
- Application
- EMEA/H/C/000312
- ATC
- R06AX27
- Official record
- www.ema.europa.eu
Indication
Aerius is indicated for the relief of symptoms associated with: allergic rhinitis (see section 5.1) urticaria (see section 5.1)
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Desloratadine Teva Authorised · Teva B.V
- 🇪🇺 Desloratadine ratiopharm Authorised · Ratiopharm GmbH
- 🇪🇺 Desloratadine Actavis Authorised · Actavis Group PTC ehf
- 🇪🇺 Dasselta Authorised · KRKA tovarna zdravil d.d. Novo mesto
- 🇪🇺 Aerinaze Authorised · Organon N.V.
- 🇪🇺 Aerius Authorised · Organon N.V.
- 🇪🇺 Neoclarityn Authorised · Organon N.V.
- 🇪🇺 Azomyr Authorised · Organon N.V.
- 🇪🇺 Desloratadine Krka Application withdrawn · KRKA tovarna zdravil d.d. Novo mesto
- 🇪🇺 Opulis Withdrawn · Schering-Plough Europe
Follow Allex
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.